While luminal tumors respond well to the hormonal therapy Tamoxifen8, and HER2 positive cancers could be properly treated with Herceptin9, triple negative breast cancers do not actively react to any available targeted modalities without severe adverse effects due to, primarily, lack of the three primary surface receptors10–13. This evidence concerns the gene ERBB2 and cancer.